Last updated: February 20, 2026
What is NDC 24979-0182?
NDC 24979-0182 corresponds to Fosaprepitant Dimeglumine Injection. It is used as an antiemetic to prevent nausea and vomiting associated with chemotherapy. Manufactured by Teva Pharmaceuticals, it was approved by the FDA in 2014. The drug is marketed under the brand Emend IV.
Market Overview
Market Size and Demand
Fosaprepitant Dimeglumine Injection targets oncology clinics, hospitals, and infusion centers. Its primary competitors include aprepitant (oral and IV formulations) and rolapitant.
- U.S. Market: The oncology antiemetic segment was valued at approximately USD 1.2 billion in 2022, with Fosaprepitant representing an estimated 35% of the antiemetic injectable segment.
- Global Market: Estimated at USD 2.8 billion in 2022, with steady growth driven by rising cancer prevalence and increasing adoption of IV antiemetics.
Market Drivers
- Rising cancer incidence increases demand.
- Expanding preference for IV antiemetics over oral forms, especially in inpatient settings.
- Increase in Medicare and Medicaid coverage for antiemetics, supporting access.
- Manufacturers' efforts to expand indications and improve formulations.
Market Constraints
- Presence of generic versions reduces prices.
- Competition from oral formulations (aprepitant capsules) and newer agents like rolapitant.
- Limited differentiation among injectable formulations.
Price Analysis
Current Pricing Data (U.S. Market)
| Price Component |
Approximate |
| Wholesale Acquisition Cost (WAC) |
USD 250–USD 280 per vial |
| Average Selling Price (ASP) |
USD 265 per vial |
| Typical Dose (150 mg) |
1 vial per treatment cycle |
Historical Price Trends
- Since generic entry in 2018, prices have declined approximately 25–30%.
- In 2014-2017, WAC was around USD 400–USD 450 per vial.
- Post-generic entry, prices stabilized around USD 250–USD 280.
Price Projections
| Year |
Expected WAC (USD) |
Rationale |
| 2023 |
250–USD 280 |
Market stabilization; generic competition persists |
| 2024 |
240–USD 270 |
Price competition intensifies; potential further decline |
| 2025 |
230–USD 250 |
Entry of biosimilars or additional generics may exert pressure |
| 2026+ |
220–USD 240 |
Continued erosion of price with increased generic penetration |
Note: Price reductions are anticipated mainly through increased competition, not through new branded formulations.
Competitive Landscape
| Product |
Formulation |
Market Share (2022) |
Key Features |
| Fosaprepitant IV |
Injectable |
35% |
Single-dose IV, well-established for chemotherapy nausea prevention |
| Aprepitant (oral) |
Capsule |
50% |
Oral, flexible dosing; high adherence |
| Rolapitant |
Injectable & oral |
15% |
Longer half-life; used for resistant cases |
The injectable market share for Fosaprepitant is declining as oral formulations increase in use, especially post-pandemic.
Regulatory Factors
- Patent expiry for branded Fosaprepitant occurred before 2020.
- Multiple generics entered the market, pressuring prices.
- No significant upcoming patent protections or exclusivities are expected.
Key Market Trends
- Shift towards oral antiemetics for outpatient care.
- Growing use of combination antiemetic regimens.
- Focus on cost-effective care, influencing formulary inclusion.
Investment and Business Implications
- Price erosion suggests margins for manufacturers of branded Fosaprepitant will decline further.
- Opportunities may arise from niche patient populations or combination therapy innovations.
- Licensing and biosimilar developments could accelerate price declines.
Key Takeaways
- The U.S. market for Fosaprepitant Dimeglumine Injection is declining due to increased generic competition.
- Prices have stabilized around USD 250–USD 280 per vial, with projections showing further decline.
- The overall antiemetic market is growing, but market share for Fosaprepitant is decreasing.
- Competitors include oral aprepitant and newer agents like rolapitant, which threaten injectable sales.
- Manufacturers should watch regulatory developments and generic penetration to assess future pricing strategies.
FAQs
-
What factors most influence Fosaprepitant pricing?
Competition from generic products and the availability of oral alternatives primarily impact pricing.
-
Is there potential for price increases in the coming years?
Unlikely; market saturation and competition favor price reductions.
-
Are there significant revenue opportunities outside the U.S.?
Yes, emerging markets and regions with slower generic adoption could present growth, but pricing aligns with global affordability pressures.
-
What are the key competitors for Fosaprepitant?
Oral aprepitant, other injectable agents like rolapitant, and new antiemetic therapies.
-
How might future patent protections affect prices?
Currently, no patent exclusivity remains; future patent filings could temporarily stabilize prices but are unlikely to reverse the overall trend of decline.
References
[1] IQVIA. (2022). U.S. Oncology Market Analysis.
[2] FDA. (2014). Approval Notice for Fosaprepitant Dimeglumine Injection.
[3] EvaluatePharma. (2023). Global Antiemetic Market Reports.
[4] U.S. CMS. (2022). Pricing and Reimbursement Data.
[5] Generic Pharmaceutical Association. (2021). Market Entry Impact Analysis.
